Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial

• Published in: Epilepsy research Vol. 121; pp. 1 - 7
• Main Authors: Ohtsuka, Yoko, Yoshinaga, Harumi, Shirasaka, Yukiyoshi, Takayama, Rumiko, Takano, Hiroki, Iyoda, Kuniaki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2016
• Subjects: Anticonvulsants - therapeutic use; Child; Child, Preschool; Double-Blind Method; Electrocardiography; Female; Humans; Japan; Lennox Gastaut Syndrome - drug therapy; Lennox–Gastaut syndrome; Long-term administration; Longitudinal Studies; Male; Neurology; Rufinamide; Safety; Seizure outcome; Time Factors; Treatment Outcome; Triazoles - therapeutic use; Lennox–Gastaut syndrome; Seizure outcome; Safety; Rufinamide; Long-term administration
• ISSN: 0920-1211; 1872-6844; 1872-6844
• DOI: 10.1016/j.eplepsyres.2016.01.002

•Long-term adjunctive rufinamide therapy was beneficial for Lennox–Gastaut syndrome.•Reduction of seizure frequency was maintained to 52 weeks in the extension study.•Of 54 patients, 38 had rufinamide-related adverse events, mainly mild and moderate.•Exacerbation of seizures and poor appetite/weight loss require attention. To evaluate the long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome (LGS) receiving adjunctive rufinamide therapy. We conducted an open-label extension study following a 12-week multicenter, randomized, double-blind, placebo-controlled study of adjunctive rufinamide therapy in Japanese patients with LGS. Fifty-four patients participated in the extension study. Seizure frequency was evaluated until 52 weeks after the start of the extension study. Adverse events (AEs) were evaluated throughout both studies. Of the 54 patients, 41 (75.9%) completed the extension study. The median duration of exposure to rufinamide was 818.0 days in all 54 patients, and 38 patients (70.4%) received rufinamide for 2 years or more. The median percent change in the frequency of tonic–atonic seizures relative to the frequency at the start of the double-blind study was −39.3% (12 weeks), −40.6% (24 weeks), −46.8% (32 weeks), −47.6% (40 weeks), and −36.1% (52 weeks). Reduction of total seizure frequency was also maintained until 52 weeks. Frequent treatment-related AEs were somnolence (20.4%), decreased appetite (16.7%), transient seizure aggravation including status epilepticus (13.0%), vomiting (11.1%), and constipation (11.1%). Adverse events were mild or moderate, except for transient seizure aggravation in three patients. Adverse events resulting in discontinuation of rufinamide were decreased appetite, drug eruption, and worsening of underlying autism. When clinically notable weight loss was defined as a decrease ≥7% relative to baseline, 22 patients (40.7%) experienced weight loss at least once during long-term observation, although weight loss was reported as an AE in only three patients. This study demonstrated a long-term benefit of rufinamide as adjunctive therapy for Japanese patients with LGS. Exacerbation of seizures and decreased appetite/weight loss should be monitored carefully.